ZDHHC9 and cancer: The identification of Treprostinil and 10‐HCPT as potent DHHC9 inhibitors opens new avenues for the development of palmitoylation‐targeted cancer therapies, while mechanistic insights into lipid‐dependent phosphatase regulation open avenues for targeting ‘undruggable’ pathways.